2022 SML OCT 8, 2022
sml_home

Your Attention Please:
Treating ADHD


All sessions will be held in Pacific Time (PT).

Saturday, October 8th



7:00 am - 8:00 am

Stimulating Discussion About ADHD Medications

CME/CE Session


David Goodman, MD

8:00 am - 9:00 am

Industry Symposium

Industry-Sponsored (non-CME/CE)


Sponsored by Intra-Cellular Therapies

9:00 am - 9:30 am

Poster Session

Industry-Sponsored (non-CME/CE)


Sponsored by Karuna Therapeutics

9:30 am - 10:30 am

Utilizing Nonstimulant Medications in the Treatment of ADHD

CME/CE Session


Andrew Cutler, MD and Jeffrey Strawn, MD

10:30 am - 11:00 am

Live Panel Q&A

CME/CE Session


David Goodman, MD; Andrew Cutler, MD and Jeffrey Strawn, MD

The content of all non-CME/CE events (Industry Symposia, Disease State Sessions, and Poster Sessions) and the views expressed therein are those of the presenting entity and not of NEI. Non-CME/CE events are not part of the scientific program and do not provide CME/CE credit. By opening a non-CME/CE event, the attendee opts in to receive follow-up information from the commercial sponsor.



Program Faculty





Andrew J. Cutler, MD


Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA

Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY


Dr. Andrew J. Cutler attended Haverford College in Philadelphia, Pennsylvania, earning a BS in Biology.  He received his MD from the University of Virginia School of Medicine, where he was also elected to the Alpha Omega Alpha (AOA) honor medical society and received the Merck Award for outstanding medical scholarship. He completed his Medical internship, Internal Medicine residency and Psychiatry residency at the University of Virginia Medical Center, where he served as Chief Resident of Psychiatric Medicine and did research on dopamine receptor pharmacology in the lab of James P. Bennett, MD, PhD.  Dr. Cutler then served as the first Assistant Professor and Director of Psychiatric Medicine at the University of Chicago.  He has been Board Certified in both Internal Medicine and Psychiatry.

Dr. Cutler has been Principal Investigator (PI) on over 400 psychiatric and medical clinical trials.  

Dr. Cutler has authored over 50 peer-reviewed scientific articles and has authored and presented over 100 abstracts/posters at various scientific meetings.  He serves as a peer reviewer for many prestigious scientific and medical journals and serves or has served on several Editorial Boards.  He has chaired or attended over 200 Scientific Advisory Boards, delivered over 3,000 pharmaceutical promotional talks and over 250 invited CME lectures and Grand Rounds presentations.  He has also done over 30 national satellite television medical education broadcasts and over 100 national medical web conferences.

Dr. Cutler is a member of several professional organizations, including the American Psychiatric Association, the Florida Psychiatric Society and the American Medical Association.  He has earned the Certified Physician Investigator (CPI) distinction from the Academy of Physicians in Clinical Research (formerly the Academy of Pharmaceutical Physicians and Investigators). He is a Fellow of the American Psychiatric Association and the Academy of Psychosomatic Medicine. He has received several professional honors and awards including the Merck Award for outstanding medical scholarship, the University of Virginia Pride Award for outstanding patient care, the William Sorum Award from the American Psychiatric Association, the Outstanding Congressional Fellow Award from the 103rd U.S. Congress, a citation from Florida Hospital for outstanding patient care and the Distinguished Clinical Professional Award from the Mental Health Association of Central Florida. He presents research posters and teaches at professional meetings and has published numerous articles in scientific and medical journals. Dr. Cutler frequently gives talks to community groups and national audiences, and often appears as a medical expert in the local and national media. 

read more +




David W. Goodman, MD, FAPA


Assistant Professor, Department of Psychiatry and Behavioral Sciences, Johns Hopkins School of Medicine, Baltimore, MD

Director and Founder, Adult Attention Deficit Disorder Center of Maryland, Baltimore, MD


Dr. David W. Goodman is an assistant professor in the department of psychiatry and behavioral sciences at Johns Hopkins School of Medicine in Baltimore, and the director and founder of the Adult Attention Deficit Disorder Center of Maryland in Baltimore, MD. His interests include adult ADHD, associated mood/anxiety/substance use disorders, and complex psychopharmacology. 

read more +




Jeffrey R. Strawn, MD


Associate Professor, Departments of Pediatrics and of Psychiatry and Behavioral Neuroscience, University of Cincinnati, College of Medicine, Cincinnati, OH 


Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents. His examination of cortical thickness in adolescents with anxiety, revealed abnormalities in cortical thickness in an ensemble of regions responsible for fear learning, fear extinction, reflective functioning (e.g., mentalization), and regulation of the amygdala. Additionally, gray matter volumes in youth with anxiety disorders are greater in the dorsal anterior cingulate and decreased in the ventrolateral prefrontal cortex), cuneus/precuneus, as well as decreased amygdala gray matter volumes in the amygdala which is consistent with his functional MRI data suggesting increased activation in youth with anxiety disorders, relative to healthy comparison subjects, during a continuous processing task with emotional and neutral distractors. Additionally, from a neurochemistry standpoint, he has demonstrated that glutamatergic tone in the anterior cingulate cortex is directly linked with anxiety symptom severity in youth with anxiety. These studies suggest that anxiety disorders are associated with structural, functional and neurochemical abnormalities with prefrontal-amygdala circuitry. By providing evidence of these structural, functional and neurochemical abnormalities, this body of work has propelled additional studies of these structures in youth who are at risk for developing anxiety disorders and in studies which have allowed the integration of psychopharmacologic treatment studies with neuroimaging evaluations of anxious youth.

In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders. As an example, with his collaborators, they demonstrated the efficacy of duloxetine in a double-blind placebo controlled trial of duloxetine which culminated in a FDA indication for duloxetine in children and adolescents with GAD (age 7-17).

read more +